ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0919

Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns

Stefanie Kurth1, Andre Tiaden1, Edveena Hanser1, Simone Häner1, Stavros Giaglis1, Florian Geier1, Dominik Burri1, Katarzyna Buczak1, Ute Heider2, Stefan Wild2, Yves Acklin1, Christian Egloff1 and Diego Kyburz3, 1University of Basel, Basel, Switzerland, 2Miltenyi Biotec, Bergisch-Gladbach, Germany, 3University Hospital Basel, Basel, Switzerland

Meeting: ACR Convergence 2025

Keywords: Fibroblasts, Synovial, Osteoarthritis, proteomics, rheumatoid arthritis, Synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0916–0933) Innate Immunity Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Extracellular vesicles (EVs) are secreted by virtually all cells and are known to carry bioactive cargo including proteins, RNA, DNA and metabolites. Analysis of the cargo of EVs derived from the synovium may provide insight into disease-specific molecular pathways of arthritis. So far, most studies characterizing EVs in disease were based on bulk analysis, neglecting the complexity of EV populations present in biofluids of patients. To investigate and characterize distinct EV subpopulations in synovial fluid of patients with rheumatoid arthritis (RA) and osteoarthritis (OA) we have established an novel immunocapture separation method based on magnetic nano-sized beads targeting cell type specific markers. CD90/THY1 was selected as a synovial fibroblast marker due to the reported contribution of CD90+ to synovitis.

Methods: EVs were isolated from synovial fluid of patients with RA and OA via size exclusion chromatography (SEC) and subsequently characterized by Nano Tracking Analyzer (NTA), NanoFlow cytometry (NanoFCM) and Western Blot (WB). For separation of a CD90+ EV population prototype anti-CD90 MicroBeads (Miltenyi Biotec) were used. WB and mass-spectrometry (MS)-based proteomics were applied to analyse the EV subpopulations. The proteomic profile of separated EV subpopulations was compared with published reference single cell RNA-Seq Data from inflamed synovial tissue. Disease specific proteomic profiles of EVs from RA and OA were compared.

Results: Using our immunocapture approach we were able to separate CD90+ EVs from synovial fluid of arthritis patients. WB confirmed a CD90 enrichment, while proteomic analysis revealed a stromal cell signature in the CD90+ EV-population, in comparison to markers for infiltrated immune cells like T cells, B cells, monocytes and neutrophils enriched in the CD90- EVs. The comparison of EV populations derived from RA and OA synovial fluid showed CD90+ EVs in both diseases. Analysis of RA-derived EVs showed a prominent neutrophil and macrophage signature, while OA enriched proteins were of fibroblast, macrophage, endothelial and epithelial cell profile. Proteomic analysis revealed several proteins enriched in RA known for their involvement in inflammation (TREM1, CXCR1, CXCR2, RETN, PADI4, LOXL3, CTSZ, MPO) or in cartilage degradation (MMP8). In contrast, in OA proteins involved in cartilage degradation and bone destruction were significantly enriched (ADAM10, FMOD, GPRC5a, INPP4N, LRP1, TNXB, SPARCL1) as well as protein candidates associated with OA pathogenesis and severity (CAPG, CTSA, LTBP1, LUM, LRP1).

Conclusion: Using a novel immunocapture approach we were able to separate cell type specific subsets of EVs from synovial fluid of arthritis patients. Proteomic analysis confirmed a stromal cell pattern in CD90+ EVs and revealed enrichment of disease specific proteins in EVs derived from RA and OA synovial fluid respectively. The ability to investigate distinct cell-type specific EV subsets in synovial fluid provides insight into pathogenetic mechanisms in the synovium and may lead to the identification of biomarkers in a liquid biopsy approach.


Disclosures: S. Kurth: None; A. Tiaden: None; E. Hanser: None; S. Häner: None; S. Giaglis: None; F. Geier: None; D. Burri: None; K. Buczak: None; U. Heider: Miltenyi Biotec, 3; S. Wild: Miltenyi Biotec, 3; Y. Acklin: None; C. Egloff: None; D. Kyburz: AbbVie/Abbott, 6, Eli Lilly, 6, Janssen, 6, Novartis, 6, UCB, 6.

To cite this abstract in AMA style:

Kurth S, Tiaden A, Hanser E, Häner S, Giaglis S, Geier F, Burri D, Buczak K, Heider U, Wild S, Acklin Y, Egloff C, Kyburz D. Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/proteomic-profiling-of-extracellular-vesicles-from-synovial-fluid-of-ra-and-oa-patients-reveals-cell-type-specific-subpopulations-and-disease-related-patterns/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/proteomic-profiling-of-extracellular-vesicles-from-synovial-fluid-of-ra-and-oa-patients-reveals-cell-type-specific-subpopulations-and-disease-related-patterns/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology